Clinical trial / 2011
Chondroitin sulphate significantly reduced cartilage volume loss starting at 6 months and bone marrow lesions at 12 months in knee osteoarthritis patients.
In a pilot multicentre trial, 69 patients with primary knee osteoarthritis and clinical signs of synovitis were randomised to 800 mg chondroitin sulphate (CS) or placebo once daily for 6 months, followed by a 6-month open-label phase where all patients received CS 800 mg daily. The CS group demonstrated significantly less cartilage volume loss than placebo at 6 months for the global knee (p=0.030), lateral compartment (p=0.015), and tibial plateaus (p=0.002), with significance maintained at 12 months. Significantly lower bone marrow lesion scores occurred in the CS group at 12 months in the lateral compartment (p=0.035) and lateral femoral condyle (p=0.044), while disease symptoms were similar between groups.
- Study type
- Randomized, double-blind, placebo-controlled pilot trial
- Who was studied
- 69 patients with primary knee osteoarthritis and clinical signs of synovitis
- What was measured
- Cartilage volume loss, bone marrow lesions, synovial membrane thickness, and disease symptoms
THE PAPER
Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP. Ann Rheum Dis, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.